Abbvie to record $4 billion impairment charges on Stemcentrx assets

Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.